TrialsgrambetaRCTs are beautiful

MELODY

2022

Nirsevimab for Prevention of RSV in Healthy Infants

In 1,490 healthy late-preterm and term infants, a single intramuscular dose of nirsevimab reduced medically attended RSV-associated lower-respiratory-tract infection compared with placebo.

Result

Medically attended RSV-LRTI
Absolute difference
3.8 points
Effect estimate

efficacy74.5

The absolute difference is derived from the event rates.

Original publication
Subtopic
RSV in infants
Design
Double-blind RCT
Relevance
Supporting: context rather than must-know.
Source
Hammitt LL, et al. N Engl J Med. 2022;386(9):837-846.doi 10.1056/NEJMoa2110275

Discussion & critique

Established universal infant RSV monoclonal prophylaxis, now standard in many countries during the RSV season.

Discussed in podcasts